The latest advances in the treatment of ovarian cancer are based on targeting DNA repair defects, as well as prospects for combining treatments (PARP inhibitors, epigenetic regulators and immune checkpoint inhibitors)

Authors
Pierre Combe, Hôpital Européen Georges Pompidou, Paris, Centre d’oncologie et radiothérapie 37, Chambray lès Tours, France
Authors
Pierre Combe, Hôpital Européen Georges Pompidou, Paris, Centre d’oncologie et radiothérapie 37, Chambray lès Tours, France
Category
Oncology
Publication type
Proceedings
Year
2019
Download the publication